2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Other hematologic neoplasm
1
Lymphoid
1
Dermatologic
1
CNS
1
Conditions
Melanoma
7
Carcinoma, Renal Cell
4
Squamous Cell Carcinoma of Head and Neck
3
Neoplasm Metastasis
3
Urinary Bladder Neoplasms
2
Triple Negative Breast Neoplasms
2
Sarcoma
2
Recurrence
2
Lymphoma, Non-Hodgkin
2
Head and Neck Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Transitional Cell
2
Carcinoma, Non-Small-Cell Lung
2
Unspecified Adult Solid Tumor, Protocol Specific
1
Stomach Neoplasms
1
Skin Neoplasms
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Neuroblastoma
1
Neoplasms
1
Metastatic Castration-resistant Prostate Cancer
1
Medulloblastoma
1
Lymphoma
1
Leukemia, B-Cell
1
Leukemia
1
Kidney Neoplasms
1
Glioma
1
Ependymoma
1
Carcinoma, Merkel Cell
1
Advanced Cancer
1
Interventions
Cyclophosphamide
346
Cytarabine
282
fludarabine phosphate
203
Methotrexate
186
Filgrastim
159
Busulfan
148
Etoposide
135
Peripheral Blood Stem Cell Transplantation
134
fludarabine
128
Rituximab
119
Radiotherapy
111
Vincristine
102
Cyclosporine
98
Daunorubicin
96
Antilymphocyte Serum
94
Dexamethasone
91
Tacrolimus
86
Mycophenolic Acid
86
Whole-Body Irradiation
81
Melphalan
79
Imatinib Mesylate
69
Idarubicin
67
Granulocyte Colony-Stimulating Factor
66
Mercaptopurine
65
Azacitidine
65
Methylprednisolone
59
Doxorubicin
58
Prednisone
57
Clofarabine
54
sargramostim
53
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia
×
bempegaldesleukin
×
Clear all
NCT04730349
2023-03-24
PIVOT IO 020
Bristol-Myers Squibb
Phase 1/2
Terminated
15 enrolled
14 charts